PRINCETON, N.J., Oct. 12, 2005 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long-term growth and income-generating focused online investment newsletter, announced today that it has provided subscribers with updates on several biotech and pharmaceutical companies including Pfizer (NYSE:PFE), Genentech (NYSE:DNA), Invitrogen (Nasdaq:IVGN), and Amgen (Nasdaq:AMGN), among others. In-depth reports on each company can also be found in the Bull Market Archives.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to The Bull Market Report's exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/?refer=BMR48
In its coverage of the energy sector, The Bull Market Report looked at the following topics, among many others:
-- What sort of upside can Pfizer expect from the Medicare Part D
prescription drug program?
-- Can Genentech's pipeline support its high PE multiple and future
price appreciation?
-- What role will the recent acquisitions of Quantum Dot and the
BioPixels business unit of BioCrystal play in Invitrogen's future
growth?
-- Is Amgen's pipeline a weak link for the company or will
developmental drugs such as panitumumab provide a good boost to
future earnings?
About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including financials, healthcare, energy, technology, and retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/?refer=BMR48
Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook," "Biotech Sector Outlook," and "Understanding the Value of Insider Trading Data."
Note: This release was published by F.P. Real Ventures I, LLC (CRD #131926). Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.